Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
4/13 First patient in Asia implanted with Second Sight's Argus II; shares ahead 29% premarket
Apr. 13, 2017 7:27 AM ET|About: Second Sight Medical P... (EYES)|By: Douglas W. House, SA News Editor
•Second Sight Medical Products (NASDAQ:EYES) announces that the first patient in Asia, a blind 40-year old Taiwanese suffering from retinal degeneration, has been implanted with the Argus II Retinal Prosthesis System through an exclusive distribution partnership with Orient Europharma Co. Ltd. and charitable support from a Taiwan-based foundation.
•Argus II converts images captured by a miniature camera mounted on the patient's glasses into a series of tiny electrical pulses that are wirelessly transmitted to an array of electrodes implanted on the surface of the retina. The pulses stimulate the remaining viable retinal cells resulting in the perception of patterns of light. The patient regains some visual capability by learning to interpret the visual patterns.
•Shares are up 29% premarket on modest volume.
https://seekingalpha.com/news/3256986-first-patient-asia-implanted-second-sights-argus-ii-shares-ahead-29-percent-premarket?app=1&uprof=51#email_link
4/10 MannKind Closes Out Worst Full Quarter Of Afrezza Sales As Management Gets Golden Parachutes
•Afrezza Sales see spike but remain below 300 weekly scripts.
•Q1 of 2017 is the worst full quarter sales in 2 years for Afrezza.
•Management seeks a golden parachute in the form of Change of Control Agreements.
https://seekingalpha.com/article/4061406-mannkind-closes-worst-full-quarter-afrezza-sales-management-gets-golden-parachutes?app=1&auth_param=1vat:1cen03s:7641fec549d1bd0ca63ec4aad720dc80&uprof=51
4/4 Flexion Therapeutics issues two new patents to strengthen intellectual property protection for Zilretta
•Flexion Therapeutics (NASDAQ:FLXN) announces the U.S. Patent and Trademark Office has issued two new patents covering the company’s lead investigational product candidate Zilretta (FX006).
•The first patent includes the treatment of a variety of indications associated with pain and inflammation. The second covers methods of manufacturing injectable extended-release microparticles that combine triamcinolone acetonide and PLGA.
•Zilretta’s composition of matter, method of use and method of manufacturing patents provide protection into 2031.
•Zilretta is being investigated as the first intra-articular, extended-release treatment for patients with osteoarthritis (OA)-related knee pain.
•Now read: 3 Possible Biotech Takeout Targets In The Second Quarter
https://seekingalpha.com/news/3255379-flexion-therapeutics-issues-two-new-patents-strengthen-intellectual-property-protection?app=1&uprof=51#email_link
4/3 MannKind: Afrezza Scripts Remain Underwhelming
•Afrezza sales remain well below 300 scripts per week.
•MannKind cash continues to dwindle.
•Some form of capital raise needs to happen in Q2
https://seekingalpha.com/article/4059918-mannkind-afrezza-scripts-remain-underwhelming?app=1&auth_param=1vat:1ce58tq:a210adf86817aeba85b37d2ab8438d1a&uprof=51
MannKind Corp.: Bleeding Out And On Its Deathbed
Stephen Fortin
•The non-inferiority of Afrezza to traditional insulin regimens in questionable.
•MNKD has been ineffective in marketing to physicians and the diabetic population alike.
•Script counts are declining, but MNKD needs an 85-fold increase in scripts just to break even.
•Further dilution is coming, and investors should steer clear of the stock.
https://seekingalpha.com/article/4059186-mannkind-corp-bleeding-deathbed?app=1&auth_param=1vat:1cdqf89:05aa6a00d7b88e6106b01c111f6c0bc9&uprof=51
MannKind: Afrezza Sales Remain Low As Q1 Comes To A Close
•Afrezza sales for the week ending March 17 were just under 260 scripts.
•Sales need to be substantially higher to impress the street and/or potential partners.
•Trend lines are simply not favorable.
https://seekingalpha.com/article/4058138-mannkind-afrezza-sales-remain-low-q1-comes-close?app=1&auth_param=1vat:1cdi6op:8428040722f5dc8cebbe13c764e14165&uprof=51
Bank Of America: Buy The Dip
Mar. 21, 2017 3:44 PM ET
•As banks fall, and the bears salivate, investors have something to think about.
•This had to happen at some point. How is BAC placed?
•Banks aren't forecasting aggressive rate hikes themselves. Focus on the core situation and see through oil and the 10 year action today
http://seekingalpha.com/article/4056911-bank-america-get-ready-buy?app=1&auth_param=1vat:1cd30l3:139e876f38885cbb7eba0089915029dc&uprof=51#alt3
What MannKind's Cash Situation Truly Looks Like
Mar. 20, 2017 2:40 PM ET
(2,404 followers)
•Company has substantial debt payments due in the coming months.
•Company cash burn rate is still about the same as I have been projecting.
•Covenants make issue more challenging.
http://seekingalpha.com/article/4056599-mannkinds-cash-concern-investors?app=1&auth_param=1vat:1cd08gt:850d60af96b6679a4ac5bbb9778fc63a&uprof=51#alt3
3/20 MannKind Beats Street With Settlement Revenue; Script Sales Still Low
Mar. 20, 2017 8:29 AM ET
•MannKind shows profit thanks to one-time event.
•Afrezza revenue in 2016 was under $2 million.
•MannKind's cash situation remains a chief concern.
http://seekingalpha.com/article/4056456-mannkind-beats-street-settlement-revenue-script-sales-still-low?app=1&auth_param=1vat:1ccviq9:40ef90f90669c3f72a7b763925e90bc2&uprof=51
3/16 MannKind's (MNKD) CEO Matthew Pfeffer on Q4 2016 Results - Earnings Call Transcript
http://seekingalpha.com/article/4056011-mannkinds-mnkd-ceo-matthew-pfeffer-q4-2016-results-earnings-call-transcript?app=1&auth_param=1vat:1ccmkl6:b68dd5fa7883ad41eb7ef0d20dfd2b95&uprof=51
3/14
MannKind's (MNKD) CEO Matt Pfeffer Presents At 29th Annual ROTH Conference (Transcript)
Mar. 14, 2017 12:54 AM ET
MannKind Corporation (NASDAQ:MNKD)
29th Annual ROTH Conference Call
March 13, 2017 8:00 PM ET
http://seekingalpha.com/article/4054768-mannkinds-mnkd-ceo-matt-pfeffer-presents-29th-annual-roth-conference-transcript?app=1&auth_param=1vat:1ccetro:0023290d5855152d48e102bdb5c5a1ca&uprof=51
Bank Of America: Historical Indicators Of A Correction
Mar. 10, 2017 3:38 AM ET
•As bank stocks surge, so too does the risk of a correction. Bank of America is up over 100% since June of last year.
•Now is the time to map out how a correction might play out using momentum indicators and historical analysis.
•History has shown that lower highs in the Relative Strength Index, correspond to choppy trading and an increase in the number of pullbacks for Bank of America.
http://seekingalpha.com/article/4054033-bank-america-historical-indicators-correction
MannKind Needs To Boost Script Sales - Will A Television Show Help?
Mar. 10, 2017 5:05 PM ET
Spencer Osborne
•Sales of Afrezza remain much lower than needed.
•Company will participate in a television show launching this summer.
•Cash issues remain critical.
http://seekingalpha.com/article/4054283-mannkind-needs-boost-script-sales-will-television-show-help?app=1&auth_param=1vat:1cc68ql:015534b333e3a8397d466db6148b9e7d&uprof=51
MannKind - Afrezza Sales Struggle As February Comes To A Close
Mar. 6, 2017 9:11 AM ET
Spencer Osborne
•Afrezza sales dip to 225 scripts for week ending February24th.
•Afrezza is now on its 3rd sales force in two years.
•Company conducted reverse split but financial concerns remain
http://seekingalpha.com/article/4052288-mannkind-afrezza-sales-struggle-february-comes-close?app=1&auth_param=1vat:1cbqrhd:e7824bc5eacd85c89d781b4a03ff10bd&uprof=51
MannKind Enacts Reverse Split At 1-For-5 Ratio: What Investors Need To Consider
Mar. 3, 2017 12:32 PM ET
Spencer Osborne
•Shareholders approved a reverse split at a special meeting.
•Authorized shares will reduce from 700 million to 140 million.
•Reverse split gets company compliant with Nasdaq.
http://seekingalpha.com/article/4051901-mannkind-enacts-reverse-split-1minus-5-ratio-investors-need-consider?app=1&auth_param=1vat:1cbja68:9b210f77602fd758a1f68f414c90c7c6&uprof=51
MannKind: Years Before Achieving Break-Even Point
Looking For Diogenes
•Readers will see the futility that MannKind is facing with their prescription stagnation issues.
•MannKind's promises versus what they have actually accomplished for investors will be contrasted.
•107 weeks and more than 2 years marketing Afrezza the barriers continue to grow for MannKind.
http://seekingalpha.com/article/4050047-mannkind-empty-saddles-empty-promises?app=1&auth_param=1vat:1cb8kvn:d4e154e034c1c5bb880c52d360a79bdc&uprof=51#alt3
MannKind - Afrezza Sales Slip As New Sales Force Starts
Feb. 17, 2017 2:54 PM ET
Spencer Osborne
•Afrezza Sales were under 240 scripts last week.
•New sales force is deployed.
•Sales are currently lower than they were when MannKind took over.
http://seekingalpha.com/article/4047256-mannkind-afrezza-sales-slip-new-sales-force-starts?app=1&auth_param=1vat:1cael8u:a989fa9fbfb8b9bef7f368920d85b576&uprof=51
MannKind, Afrezza Sales, And 'Free Beer Tomorrow'
Feb. 10, 2017 4:48 PM ET
Spencer Osborne
Growth, value, special situations, momentum
•Afrezza sales stay below 300 scripts per week.
•The Nasdaq clock is winding down.
•Cash needs to remain as the critical focus.
http://seekingalpha.com/article/4045005-mannkind-afrezza-sales-free-beer-tomorrow?app=1&auth_param=1vat:1c9sd9j:8bbe71d6eec286c5e535468f153f7623&uprof=51
MannKind - Afrezza Sales Improve Slightly, But Not Enough To Excite Investors
Feb. 3, 2017 4:09 PM ET
Spencer Osborne
•Afrezza scripts remain below 300.
•Company is shifting to new sales force.
•Reverse Split is center stage.
http://seekingalpha.com/article/4042601-mannkind-afrezza-sales-improve-slightly-enough-excite-investors?app=1&auth_param=1vat:1c99sci:0c3d38a71440b519e8a1f497c1ba64be&uprof=51
MannKind: The Saga Of Smoking Guns
Feb. 3, 2017 12:05 PM ET
Looking For Diogenes
•MannKind has taken the reverse split approach to salvage their listing on Nasdaq.
•MannKind has told investors there is an efficacy issue and now they tell you why there is this issue.
•Asking for a label change for a fast-acting insulin designation carries a major downside that questions the future marketing for Afrezza.
http://seekingalpha.com/article/4042502-mannkind-saga-smoking-guns?app=1&auth_param=1vat:1c99e32:1005a4fc7d0fd11db17c76357c316d7e&uprof=51
MannKind Announces Plans For Reverse Split
Feb. 2, 2017 9:01 AM ET
Spencer Osborne
•MannKind intends to conduct a reverse split to comply with Nasdaq.
•The company will hold a meeting February 24 to vote on the reverse split.
•The company is seeking a ratio between 1-for-3 and 1-for-10.
http://seekingalpha.com/article/4041916-mannkind-announces-plans-reverse-split?app=1&auth_param=1vat:1c96eup:78b5bc1f04b26314aad8f4ac6bcbac17&uprof=51
Afrezza Sales Still Low As MannKind Prepares For Investor Update
Jan. 27, 2017 5:32 PM ET
Spencer Osborne
•Afrezza sales are not picking up with the new year.
•Sales registered about 225 scripts for the week ending January 20.
•The company will host an investor update February 1 after the market close.
http://seekingalpha.com/article/4040301-afrezza-sales-still-low-mannkind-prepares-investor-update?app=1&auth_param=1vat:1c8nijv:08b648996504509a77136adc062776e0&uprof=51
MannKind: Afrezza Sales Start Off 2017 Modestly. Will A Bigger Sales Force Make A Material Difference?
Jan. 17, 2017 5:32 PM ET
Spencer Osborne
•Sales of Afrezza start off the year with about 240 scripts.
•MannKind is expanding sales force.
•Insurance coverage sees a modest improvement.
http://seekingalpha.com/article/4037443-mannkind-afrezza-sales-start-2017-modestly-will-bigger-sales-force-make-material-difference?li_source=LI&li_medium=liftigniter-widget
MannKind Sells Building, Extends Cash Runway: The Good And The Bad
Jan. 12, 2017 7:16 PM ET
Spencer Osborne
•Company enters agreement to sell office building for $17.3 million.
•Cash from the deal could extend financial runway by 6 to 10 weeks.
•Both bulls and bears have stances on the news, as market reaction is muted.
http://seekingalpha.com/article/4036529-mannkind-sells-building-extends-cash-runway-good-bad?app=1&auth_param=1vat:1c7g73p:5a59324607297ef5e5c4ffe277b0ee95&uprof=51
MannKind's (MNKD) CEO Matt Pfeffer Presents at JPMorgan Healthcare Conference (Transcript)
Jan. 12, 2017 3:39 PM ET
JPMorgan Healthcare Conference Call
January 12, 2016 13:00 ET
Executives
Matt Pfeffer - Chief Executive Officer
Analysts
Shawn Fu - JPMorgan
http://seekingalpha.com/article/4036493-mannkinds-mnkd-ceo-matt-pfeffer-presents-jpmorgan-healthcare-conference-transcript?part=single
MannKind Afrezza Sales - Closing Out The Year By The Numbers
Jan. 9, 2017 7:43 AM ET
Spencer Osborne
•Afrezza sales remain under 300 per week.
•Q4 sales were just 3,573 scripts.
•Numbers need to shift in a compelling way quickly.
http://seekingalpha.com/article/4035177-mannkind-afrezza-sales-closing-year-numbers?app=1&auth_param=1vat:1c771ci:f6bb5e0d1ca66b110f61bcd9c26d3369&uprof=51
1/3 MannKind's $1M Milestone: Good News, But Barely
Spencer Osborne
•MannKind received a $1 million milestone payment from Receptor Life Sciences on December 30.
•The amount of the milestone is lower than many MannKind bulls were hoping for.
•At the current cash burn rate, the $1 extends the company's financial runway by 3 or 4 days.
http://seekingalpha.com/article/4034051-mannkinds-1m-milestone-good-news-barely#alt3
1/3 Does A Possible Label Change On Afrezza Mean More To Investors Than To Doctors And Insurers?
Jan. 3, 2017 12:17 PM ET
Spencer Osborne
•The company has touted a possible label change in 2017.
•The scope of a label change, if approved, can make a big difference.
•A label change is not likely to happen prior to a cash crunch for the company.
http://seekingalpha.com/article/4033973-afrezzas-potential-label-change-ultra-fast-ultra-important#alt1
No Sizzle To The Afrezza Fizzle
Dec. 30, 2016 4:22 PM ET
Looking For Diogenes
•MannKind management's many promises have gone unfilled.
•Various data outline the failures for MannKind's 2.0 relaunch of Afrezza.
•Included is a chart projecting a 10% growth rate, showing that even this meager capture rate will not achieve profitability for MannKind.
http://seekingalpha.com/article/4033526-mannkinds-affrezza-fizzling#alt1
MannKind: Will Afrezza's Holiday Lull Transform Into A New-Year Surge?
Dec. 27, 2016 12:00 PM ET
Spencer Osborne
?Following (2,344 followers)
Growth, value, special situations, momentum
•Afrezza sales remain below 300 scripts per week.
•New year will supposedly bring more sales reps and some advertising.
•Cash levels and NASDAQ listing remain critical items to watch.
http://seekingalpha.com/article/4032874-mannkind-will-afrezzas-holiday-lull-transform-new-year-surge?app=1&auth_param=1vat:1c657i2:4d6bafa406b74b5ebb48fc2eb3beb83e&uprof=51
MannKind: Afrezza Sales Still Having Trouble With Traction
Dec. 18, 2016 5:18 PM ET
Spencer Osborne
•Sales remain under 300 scripts per week.
•Refill traction remains critical issue.
•Poor Sales, NASDAQ listing, and Cash remain top concerns.
http://seekingalpha.com/article/4031266-mannkind-afrezza-sales-still-trouble-traction?app=1&auth_param=1vat:1c5e2pr:39e5e0f31cfcc1e8edb97044c11014c7&uprof=51
MannKind: Thanksgiving Week Takes Toll On Afrezza Scripts
Dec. 2, 2016 12:55 PM ET
|
About: MannKind Corporation (MNKD)
Spencer Osborne
•Afrezza scripts drop to about 220.
•New Afrezza scripts come in at less than 100.
•Lack of traction and tax selling could be the story of this equity for the next few weeks.
http://seekingalpha.com/article/4027865-mannkind-thanksgiving-week-takes-toll-afrezza-scripts?app=1&auth_param=1vat:1c43dcr:985c292f7a63d632eb0564370acfe4f3&uprof=51
2 Key Reasons MannKind Needs To Remain On Nasdaq
Nov. 29, 2016 5:19 PM ET
Spencer Osborne
•Company is outside of compliance with NASDAQ listing requirements.
•Company must gain compliance by Mid March.
•Exchange listing is usually critical in raising funds and being included in an index.
http://seekingalpha.com/article/4027112-2-key-reasons-mannkind-needs-remain-nasdaq?app=1&auth_param=1vat:1c3rvo1:67d6f132db1acb4648ab89f5ad63d447&uprof=51
MannKind Finally Comes Clean And Faces Reality
Nov. 29, 2016 12:15 PM ET
Looking For Diogenes
•MannKind made some key admissions in its recent quarterly report.
•The current plan to resolve the company's issues might be on the wrong track.
•Myths don't offer sound business practices for investors.
http://seekingalpha.com/article/4026994-mannkind-finally-comes-clean-faces-reality?app=1&auth_param=1vat:1c3rc59:cee5600e40e6305096954f63f415494c&uprof=51#alt1
MannKind - Afrezza Scripts Still Low As Year-End Holidays Approach
Nov. 28, 2016 4:55 PM ET
Spencer Osborne
•Scripts for the week ending November 18th were under 300.
•Major holidays will be a drag on scripts for the remainder of 2016.
•Cash burn, Nasdaq listing, and slow sales translate to poor equity performance.
http://seekingalpha.com/article/4026777-mannkind-afrezza-scripts-still-low-year-end-holidays-approach?app=1&auth_param=1vat:1c3p9v0:a9556fbe2d898d2a0051458723c05bc3&uprof=51
MannKind's Earnings Beat Doesn't Change Much
Nov. 23, 2016 8:29 AM ET
David Butler
•MannKind Pharmaceuticals recently had some life in its stock price after reporting a surprise earnings beat.
•This 3rd quarter surprise had nothing to do with sales of Afrezza. The money came from old licensing agreements with Sanofi.
•The cash was a one-time thing, and will not help the company's progressively abysmal sales.
http://seekingalpha.com/article/4025858-mannkinds-earnings-beat-change-much?app=1&auth_param=1vat:1c3b6ei:307e913389bfcfa4d2e541c95a90441e&uprof=51
MannKind's Afrezza Sales Remain Below 300 Scripts - Can The Company Increase Sales Soon?
Nov. 21, 2016 12:54 PM ET
Spencer Osborne
•Afrezza sales for week ending 11/11 were about 290.
•Refills remain problematic.
•Projecting sales through Q2 shows that problems remain.
http://seekingalpha.com/article/4025196-mannkinds-afrezza-sales-remain-300-scripts-can-company-increase-sales-soon?app=1&auth_param=1vat:1c36d80:cc19cc5c7f2dfd994fd31546519c5e7a&uprof=51
MannKind - Afrezza Scripts Increase, Runway Extended, But Sales Will Still Be Problematic
Nov. 14, 2016 11:09 AM ET
Spencer Osborne
•Afrezza scripts sales increase to just under 300 for week ending November 4th.
•Company gets runway extended via settlement with Sanofi.
•Sales projections remain problematic, as does potential NASDAQ de-listing.
http://seekingalpha.com/article/4023137-mannkind-afrezza-scripts-increase-runway-extended-sales-will-still-problematic?app=1&auth_param=1vat:1c2jodq:2a881efeba16dead8182f523d30545a9&uprof=51
MannKind Announces Q3 Profit, Extends Financial Runway, But Still Faces Headwinds
Nov. 11, 2016 3:34 PM ET
Spencer Osborne
•MannKind announced a profit of $126.5 million thanks to a one-time event.
•Afrezza sales deliver just $573,000 in revenue for the quarter.
•The Street was expecting a loss of $0.06 (absent one-time events).
http://seekingalpha.com/article/4022680-mannkind-announces-q3-profit-extends-financial-runway-still-faces-headwinds?app=1&auth_param=1vat:1c2cas2:8c25f4c62caaa382319454a7903ef2cb&uprof=51
MannKind's (MNKD) CEO Matthew Pfeffer on Q3 2016 Results - Earnings Call Transcript
Nov. 10, 2016 12:32 AM ET
|
18 comments
|
About: MannKind Corporation (MNKD)
Q3 2016 Earnings Summary
http://seekingalpha.com/article/4021887-mannkinds-mnkd-ceo-matthew-pfeffer-q3-2016-results-earnings-call-transcript?li_source=LI&li_medium=liftigniter-widget
MannKind: Afrezza Sales Fizzle Going Into Quarterly Call
Nov. 4, 2016 3:45 PM ET
•Script sales for week ending October 28 were just below 260.
•New scripts seeing minimal growth as refills continue decline.
•By my estimation cash is down to just $23 million.
http://seekingalpha.com/article/4019771-mannkind-afrezza-sales-fizzle-going-quarterly-call?app=1&auth_param=1vat:1c1ppaq:0a0322de4a641f2bcf205ef82bea4682&uprof=51
MannKind's Q3 Conference Call - What Investors Should Look For
Nov. 1, 2016 1:08 PM ET
Spencer Osborne
•The call will be November 9 at 5:00 PM EST.
•Q3 2016 will be the first quarter where MannKind completely controlled marketing of Afrezza.
•Investors should look for some critical information not seen in the financials.
http://seekingalpha.com/article/4017635-mannkinds-q3-conference-call-investors-look?app=1&auth_param=1vat:1c1hj17:7f9d139e03890fd38d738b1771e5fa58&uprof=51
MannKind Stock Price Slides As Afrezza Sales Lose Traction
Oct. 28, 2016 1:27 PM ET
Spencer Osborne
•MannKind stock is below 50 cents again.
•Afrezza sales slip to levels seen three months ago.
•Cash and de-listing remain top concerns.
http://seekingalpha.com/article/4016414-mannkind-stock-price-slides-afrezza-sales-lose-traction?app=1&auth_param=1vat:1c172l2:5817e1fe7b98d97b74b39d4c72d9c814&uprof=51
*****MannKind - Afrezza Scripts Dip Again - About As Exciting As Watching Paint Dry
Oct. 21, 2016 2:11 PM ET
Spencer Osborne
•Afrezza Scripts dip back below 300 to 270.
•Script remains very flat approaching 4 months into re-launch.
•Stock is susceptible to active traders playing spikes and dips.
http://seekingalpha.com/article/4013920-mannkind-afrezza-scripts-dip-exciting-watching-paint-dry?app=1&auth_param=1vat:1c0kmjo:7d4cbd1f5f7a8f833d88e52f7ccd57b4&uprof=51
******MannKind - Afrezza Scripts Finally Pass 300 - Pace Remains Very Slow
Oct. 14, 2016 3:14 PM ET
Spencer Osborne
•Afrezza Scripts Pass 300 mark for first time since re-launch.
•Company cash remains a concern.
•18% of NASDAQ listing compliance window is now gone
http://seekingalpha.com/article/4012220-mannkind-afrezza-scripts-finally-pass-300-pace-remains-slow?app=1&auth_param=1vat:1c029sp:63c132868c245ffa82307d4e079d0002&uprof=51#alt1
*** ** MannKind Finishes Q3 With Weak Afrezza Sales
Oct. 7, 2016 12:55 PM ET
|Follow this author
•Sales of Afrezza never passed 300 during the quarter.
•Afrezz started q3 with 266 scripts and got to 291 over the next three months.
•First quarter of Afrezza re-launch was worst full quarter to date
http://seekingalpha.com/article/4010849-mannkind-q3-weak-afrezza-sales#alt1
***** MannKind-Afrezza Scripts Slide: What To Focus On
Sep. 30, 2016 2:31 PM ET
Spencer Osborne
•Afrezza scripts slide to less than 250.
•Re-launch of Afrezza is now 12 weeks old and not making much progress.
•Cash continues to dwindle away as sales performance underwhelms
http://seekingalpha.com/article/4009462-mannkind-afrezza-scripts-slide-investors-need-think-sooner-rather-later?app=1&auth_param=1vat:1buta3l:8464ab9ef073320f4182a286c6e2e337&uprof=51#alt3
Followers
|
2
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
216
|
Created
|
08/18/16
|
Type
|
Premium
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |